Search Results

MC# 21-21
A Phase Ib/II, Open-label, Multi-center Study of ERAS-007 in Patients with Advanced or Metastatic Solid Tumors

MC# 21-25
An Open Label, Phase I Dose Escalation Trial, with Dose Confirmation and Expansion, of BI 1810631 as Monotherapy in Patients with Advanced or Metastatic Solid Tumors with HER2 Aberrations

MC# 21-26
A Phase I, Open-Label, Dose Escalation, and Cohort Expansion Study to Evaluate the Safety, Tolerability, Pharmacokinetics (PK) and Clinical Activity of DT2216, an Antiapoptotic Protein Targeted Degradation Compound, in Patients with Relapsed or Refractory Malignancies

MC# 21-27
A Phase Ia/Ib, Open-Label, Multicentre Dose-Escalation and Expansion Study to Investigate the Safety, Pharmacokinetics and Preliminary Efficacy of BI 1823911 as a Monotherapy and in Combination with Other Anti-Cancer Therapies in Patients with Advanced or Metastatic Solid Tumors Expressing KRAS G12C Mutation

MC# 21-29
A Phase I Study to Evaluate the Safety and Tolerability of GS-1811, an Afucosylated Anti-CCR8 Monoclonal Antibody, as Monotherapy and in Combination with Pembrolizumab in Adults with Advanced Solid Tumors

MC# 21-30
An Open-label, Fixed-sequence Study to Assess the Effect of Repeated Doses of Capivasertib on the Pharmacokinetics of Oral Midazolam (a CYP450 3A Probe) in Patients With Advanced Solid Tumours Harbouring Alterations in the PI3K/AKT/PTEN Pathway

MC# 21-37
A Phase I, First in Human, Open-label, Dose Escalation and Dose Expansion Study of TST005 in Patients with Locally Advanced or Metastatic Solid Tumors

MC# 21-41
A Phase I Study of ASP1570 in Participants with Advanced Solid Tumors

MC# 21-42
A Phase I Study of The Safety and Tolerability of COM902 in Subjects with Advanced Malignancies

MC# 21-44
A Phase I Study Investigating AGEN1777 as a Single-Agent and in Combination with PD-1 Inhibition in Patients with Advanced Solid Tumors

MC# 22-02
First-in-human Study of ATR Inhibitor IMP9064 Monotherapy and in Combination with PARP Inhibitor Senaparib in Patients with Advanced Solid Tumors

MC# 18-26
A Phase I/II Study of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation

MC# 20-15
A Phase I First-Time-in-Human, Open-Label Study of GSK6097608 Administered as Monotherapy and in Combination with Anticancer Agents in Participants with Advanced Solid Tumors

MC# 20-25
A Phase I Study of SRF617 in Patients With Advanced Solid Tumors

MC# 20-33
A Phase Ib/II, Open-label, Multicenter, Dose Escalation and Dose Expansion Study of NKTR- 255 in Combination with Cetuximab as a Salvage Regimen for Solid Tumors

MC# 21-17
A Phase I/II Dose Escalation and Dose Expansion Study of BA3021 Alone and in Combination with Nivolumab in Patients with Advanced Solid Tumors

MC# 21-36
An Open-Label, Multicenter, Phase I Study Of IGM-8444 as a Single Agent and in Combination in Subjects with Relapsed and/or Refractory Solid Cancers

MC# 21-39
A Phase I/IIa Study of the SV-BR-1-GM Regimen in Metastatic or Locally Recurrent Breast Cancer Patients in Combination with INCMGA00012 and Epacadostat

MC# 19-25
A Phase I open-label, multicenter dose escalation study of MT-5111 in subjects with previously treated advanced HER2-positive solid tumors

MC# 19-27
A Phase I Study of AGEN2373, an Anti-CD137 Monoclonal Antibody in Subjects with Advanced Cancer

MC# 19-33
A Phase I, Open-label Single-dose Pharmacokinetic and Safety Study of Oral Tazemetostat in Subjects with Moderate and Severe Hepatic Impairment with Advanced Malignancies

MC# 20-17
A Phase I, Open-Label, Multiple-Ascending Dose Study of the Safety and Tolerability of T3011 in Advanced Cutaneous or Subcutaneous Malignancies

MC# 21-11
A Multicenter, Phase I, Open-Label Study of SQ3370 in Patients with Advanced Solid Tumors

MC# 19-21
A Phase I/IIa Open-label, Multicenter, Dose Escalation and Dose Expansion Study of the Safety, Tolerability, and Pharmacokinetics of HPN536 in Patients with Advanced Cancers Associated with Mesothelin Expression Who Have Failed Standard Available Therapy

MC# 20-01
A Phase I First-in-Human Study with ABBV-155 Alone and in Combination with Taxane Therapy in Adults with Relapsed and/or Refractory Solid Tumors